20,949 research outputs found
An Efficient Algorithm for Mining Frequent Sequence with Constraint Programming
The main advantage of Constraint Programming (CP) approaches for sequential
pattern mining (SPM) is their modularity, which includes the ability to add new
constraints (regular expressions, length restrictions, etc). The current best
CP approach for SPM uses a global constraint (module) that computes the
projected database and enforces the minimum frequency; it does this with a
filtering algorithm similar to the PrefixSpan method. However, the resulting
system is not as scalable as some of the most advanced mining systems like
Zaki's cSPADE. We show how, using techniques from both data mining and CP, one
can use a generic constraint solver and yet outperform existing specialized
systems. This is mainly due to two improvements in the module that computes the
projected frequencies: first, computing the projected database can be sped up
by pre-computing the positions at which an symbol can become unsupported by a
sequence, thereby avoiding to scan the full sequence each time; and second by
taking inspiration from the trailing used in CP solvers to devise a
backtracking-aware data structure that allows fast incremental storing and
restoring of the projected database. Detailed experiments show how this
approach outperforms existing CP as well as specialized systems for SPM, and
that the gain in efficiency translates directly into increased efficiency for
other settings such as mining with regular expressions.Comment: frequent sequence mining, constraint programmin
Coalition Governments, Cabinet Size, and the Common Pool Problem: Evidence from the German States
Current Accounts in Europe: Implications of the External Imbalances for the Future of the Common Monetary Policy
Electrostatics in a simple wormhole revisited
The electrostatic potential generated by a point charge at rest in a simple
static, spherically symmetric wormhole is given in the form of series of
multipoles and in closed form. The general potential which is physically
acceptable depends on a parameter due to the fact that the monopole solution is
arbitrary. When the wormhole has Z2-symmetry, the potential is completely
determined. The calculation of the electrostatic self-energy and of the
self-force is performed in all cases considered.Comment: 16 pages, no figure
Financial Liberalization, Growth, Productivity and Capital Accumulation: The Case of European Integration
Economic evaluation of ASCOT-BPLA: Antihypertensive treatment with an amlodipine-based regimen is cost-effective compared to an atenolol-based regimen
Copyright © 2010 BMJ Publishing Group Ltd & British Cardiovascular Society. Internal or personal use of this material is permitted. However, permission to reprint/republish this material must be obtained from the Publisher.Objective: To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden.
Design: A prospective, randomised trial complemented with a Markov model to assess long-term costs and health effects.
Setting: Primary care.
Patients: Patients with moderate hypertension and three or more additional risk factors.
Interventions: Amlodipine 5–10 mg with perindopril 4–8 mg added as needed or atenolol 50–100 mg with bendroflumethiazide 1.25–2.5 mg and potassium added as needed
Main outcome measures: Cost per cardiovascular event and procedure avoided, and cost per quality-adjusted life-year gained.
Results: In the UK, the cost to avoid one cardiovascular event or procedure would be €18 965, and the cost to gain one quality-adjusted life-year would be €21 875. The corresponding figures for Sweden were €13 210 and €16 856.
Conclusions: Compared with the thresholds applied by NICE and in the Swedish National Board of Health and Welfare’s Guidelines for Cardiac Care, an amlodipine-based regimen is cost effective for the treatment of hypertension compared with an atenolol-based regimen in the population studied.The study was supported by the principal funding source, Pfizer, New York, USA
- …